Who is sponsoring NCT03082625?

NCT03082625 is sponsored by Sir Charles Gairdner Hospital.

What drugs are being tested in NCT03082625?

Interventions in NCT03082625: Transdermal Magnesium, Placebo.

What condition does NCT03082625 study?

NCT03082625 studies Chronic Kidney Diseases, End Stage Renal Disease, Dialysis Related Complications.

Is NCT03082625 still recruiting?

NCT03082625 is currently status unknown. Last updated 17 March 2017.

Last reviewed 2017-03-17 · How we verify

NCT03082625

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Topical Magnesium and Muscle Cramps in Dialysis Patients.

Status unknown Phase 2 Last updated 17 March 2017

What this trial tests

Phase 2 trial testing Transdermal Magnesium in Chronic Kidney Diseases in 40 participants. Status unknown.

Timeline

1 May 2017

Primary endpoint
31 March 2018

31 December 2018

Quick facts

Lead sponsor	Sir Charles Gairdner Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	40
Start date	1 May 2017
Primary completion	31 March 2018
Estimated completion	31 December 2018

Drugs / interventions tested

Transdermal Magnesium — full drug profile →
Placebo

Conditions studied

Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
End Stage Renal Disease — all drugs for End Stage Renal Disease →
Dialysis Related Complications — all drugs for Dialysis Related Complications →

Sponsor

Sir Charles Gairdner Hospital

Who can join

18 and older, any sex, with Chronic Kidney Diseases or End Stage Renal Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Oral magnesium supplementation has been widely used in the treatment of muscle cramps. Muscle cramps are common in dialysis patients but are not satisfactorily prevented by oral magnesium. Transdermal administration of magnesium has been promoted as a potential treatment for muscle cramps but this has not been investigated rigorously. We aim to evaluate the effectiveness of transdermal magnesium supplementation in reducing cramp frequency and severity. We will recruit current haemodialysis patients who suffer from muscle cramps into a randomised, placebo-controlled, cross-over design trial. Each intervention period will last 8 weeks with a 4-week washout period in between. We will measure muscle cramp frequency, duration and severity as the primary outcomes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Magnesium for skeletal muscle cramps.
Garrison SR, Korownyk CS, Kolber MR, Allan GM, et al · · 2020 · cited 33× · PMID 32956536 · DOI 10.1002/14651858.cd009402.pub3

Verify or expand the search:

Other recruiting trials for Chronic Kidney Diseases

Currently open trials in the same condition.

NCT06593392 — Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus · Phase 2 · recruiting
NCT07358572 — Eye-Brain-Kidney in CKD · recruiting
NCT06463483 — Automated Insulin Delivery in Adults With Advanced Kidney Disease · NA · recruiting
NCT06927024 — Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD) · NA · recruiting
NCT07115953 — Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension · NA · recruiting

Other Sir Charles Gairdner Hospital trials

Trials by the same sponsor.

NCT01478698 — The Safety and Tolerability of Intra-abdominal t-PA and DNase on Peritonitis in Peritoneal Dialysis Patients · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03082625 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sir Charles Gairdner Hospital
Last refreshed: 17 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03082625.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing